CorMedix Inc
NASDAQ:CRMD

  • LAST PRICE
    5.4100
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    5.4000/ 5
  • Ask / Lots
    5.4500/ 1
  • Open / Previous Close
    5.8500 / 5.4100
  • Day Range
    5.3600
    5.8900
  • 52 Week Range
    2.5700
    7.0000
  • Volume
    896,049

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Yesterday

      Show headlines and story abstract

    • 19 hours ago by GlobeNewswire
      Companies Mentioned: CRMD

    • 19 hours ago by Dow Jones
      Companies Mentioned: CRMD
      Short-term investments $ 23,370,989 $ 32,388,130 Total Assets $ 68,023,742 $ 82,059,957 Total Liabilities $ 10,011,022 $ 11,917,528 Accumulated deficit $(336,166,136) $(321,700,013) Total Stockholders' Equity $ 58,012,720 $ 70,142,429 CORMEDIX INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) For the Three Months Ended March 31, -------------------------------- 2024 2023 Cash Flows from Operating Activities: Net loss $ (14,466,123) $ (10,567,226) Net cash used in operating activities (17,310,294) (10,393,886) Cash Flows Used in Investing Activities: Net cash provided by (used in) investing activities 8,944,932 (14,686,805) Cash Flows from Financing Activities: Net cash (used in) provided by financing activities (97,118) 7,200,406 Net Decrease in Cash and Cash Equivalents (8,463,285) (17,878,001) Cash and Cash Equivalents and Restricted Cash - Beginning of Period 43,823,192 43,374,745 Cash and Cash Equivalents and Restricted Cash - End of Period $ 35,359,907 $ 25,496,744

    • 19 hours ago by Dow Jones
      Companies Mentioned: CRMD
      Short-term investments $ 23,370,989 $ 32,388,130 Total Assets $ 68,023,742 $ 82,059,957 Total Liabilities $ 10,011,022 $ 11,917,528 Accumulated deficit $(336,166,136) $(321,700,013) Total Stockholders' Equity $ 58,012,720 $ 70,142,429 CORMEDIX INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) For the Three Months Ended March 31, -------------------------------- 2024 2023 Cash Flows from Operating Activities: Net loss $ (14,466,123) $ (10,567,226) Net cash used in operating activities (17,310,294) (10,393,886) Cash Flows Used in Investing Activities: Net cash provided by (used in) investing activities 8,944,932 (14,686,805) Cash Flows from Financing Activities: Net cash (used in) provided by financing activities (97,118) 7,200,406 Net Decrease in Cash and Cash Equivalents (8,463,285) (17,878,001) Cash and Cash Equivalents and Restricted Cash - Beginning of Period 43,823,192 43,374,745 Cash and Cash Equivalents and Restricted Cash - End of Period $ 35,359,907 $ 25,496,744

  • May 6, 2024

Peers Headlines